オーストラリア OPAL データセットにおける関節リウマチ患者の第一選択薬としてのバリシチニブの有効性
ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577
Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.
The analysis of OPAL, an Australian rheumatology dataset, show real-world data on the longevity of baricitinib and TNF inhibitors as a first-line therapy. A second analysis compared first-line baricitinib monotherapy and first-line baricitinib combination therapy.
Keywords:
